IMO this partnership with Yale is the core business that has the cancer drug technology and IP (Novogen)and now the delivery technology inclusive of ovarian stem cell specialisation (Yale).
A perfect fit end to end.
This core business and the way it is setup will then partner with a major pharmaceutical and major investor to fund development and progress.
This is where the roadshows in December fit in.
sec filing - novogen yale uni joint venture , page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)